Feed Articles

3 stocks Goldman Sachs recommends buying

We have crossed the halfway point of the year and the stock market is still breaking new records. With inflation falling for the first time in four years, the way is clear for a possible earlier-than-expected cut in interest rates, sparking investor interest. However, market leaders might not be the ones to see us through the first half of 2024. The rise of technology stocks could take a back seat.

An overview of the current market situation

The technology sector, which dominated the market, is now experiencing a weakening. The iShares Semiconductor ETF has seen a decline of nearly 9% since reaching a record high last week. Goldman Sachs expects the market to start moving away from technology stocks. Back in April, the investment bank warned that it was time to look elsewhere for investment opportunities. Although the sector has been resilient for months, now may be the time to follow analysts' advice.

Goldman Sachs investment tips

Goldman Sachs has picked three stocks it has assigned a "buy" rating to, with target prices suggesting double-digit returns over the next year. Which 3 stocks are they?

Exact Sciences $EXAS

Exact Sciences (NASDAQ), a company focused on cancer testing and diagnostics, is forecast to grow 50% over the next year. Goldman Sachs cut its price target to $75 per share from $88, but reiterated its "buy" rating. The company's stock is down 34% since the beginning of the year on concerns about competitive testing.

Exact Sciences is a leader in colon cancer testing. Although colonoscopy remains the gold standard for accuracy, the invasive nature of the test makes it a less than optimal choice. Exact Sciences' tests represent a second-best option. Although Guardant Health is developing a blood test for colon cancer that has been recommended for approval by an FDA advisory committee, so-called bench tests are considered more accurate, especially for early screening.

Amazon $AMZN

Amazon (NASDAQ) recently wrapped up its latest Prime Day event, which the company says generated the biggest sales in the history of such events. Analysts predicted sales of approximately $14 billion during the two-day event. Goldman Sachs raised its target price to $250 and reiterated a "buy" rating.

Amazon's performance underscores the health of consumers, as second-quarter results show. Despite some weaker markets, e-commerce remains resilient. Amazon is also reporting higher retail margins and rising operating income. In addition to continued growth in cloud services, Goldman Sachs sees Amazon as a solid growth stock.

Snowflake $SNOW

Analyst Kash Rangan recently reiterated a "buy" rating on data warehouse provider Snowflake (NYSE) with a $220 per share price target. The stock was added to the list with high conviction to buy.

Unfortunately, before the revelation of the massive hack of AT&T data hosted on Snowflake's servers. The hack affected virtually all AT&T customers, raising concerns about data security. As a result, Snowflake shares have fallen 30% this year as investors expressed concerns about competitive pressures.

Yet Wall Street still maintains an optimistic outlook for Snowflake stock. Analysts predict an annual target price of $197 per share.

Disclaimer: You will find a lot of inspiration on Bulios, but stock selection and portfolio construction is up to you, so always conduct a thorough analysis of your own.

Source..

A community member's personal view, not investment advice. Community Guidelines

Follow Bulios on Google News

Be among the first to discover new analyses, news and market moves.

Follow

Recommended articles

Read more

Expensive oil was supposed to sink them; these 3 cruise lines instead report records and expect further growth

Oil this year soared to $138 per barrel, and cruise ships, which burn hundreds of thousands of tons of it annually, were supposed to be the first to suffer. Instead, all three largest cruise operators raised their profit outlooks, yet for a dollar of profit the market pays almost twice as much for…

MC
Milan Charvat
· 5h
Read more
BLACK

Man with Parkinson's stood up and walked away after an injection. The drugmaker's stock still fell 20%

A man with Parkinson's who couldn't get up from a chair walked out through the door on his own after a year of treatment with his own cells. The company behind the treatment raised $140.6 million in its IPO, and three weeks later its stock is 20% cheaper, even though there hasn't been a single…

MC
Milan Charvat
· 10h
Read more
BLACK

Dividends Above 10%? No Problem for These Stocks

A yield of over 15% a year sounds almost unbelievable in the stock market, yet several established US-listed securities are offering just that today. Mortgage REITs and leveraged bond funds earn money from the difference between the yield on mortgages or bonds and the cost of short-term financing,…

KJ
Kryštof Jáně
· 13h

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy